肠源性高草酸尿症的病理生理与治疗
肠源性高草酸尿症由多种促进脂肪吸收不良的胃肠道疾病引起,导致膳食草酸吸收增加和尿草酸排泄增多,增加肾结石风险,严重者可致慢性肾脏病甚至肾衰竭。近几十年来,因减重手术增加,其患病率上升。本系统综述由肾脏健康倡议项目支持,描述其病理生理、病因、结局和治疗,现有治疗限于纠正胃肠道疾病、强化饮食调整和钙盐结合草酸,但缺乏对临床硬结局的证据。
要点
- 肠源性高草酸尿症继发于脂肪吸收不良,增加肾结石和慢性肾脏病风险。
- 减重手术的增多使肠源性高草酸尿症患病率上升。
- 现有治疗证据限于纠正胃肠道疾病、饮食调整和钙盐,缺乏硬结局证据。
核心结论
- 肠源性高草酸尿症可导致肾结石、慢性肾脏病甚至肾衰竭,现有治疗对临床显著结局的证据缺乏,需进一步研究。
研究设计与样本
- 系统综述,作为肾脏健康倡议项目的一部分,描述肠源性高草酸尿症的病理生理、病因、结局和治疗。
主要发现
- 肠源性高草酸尿症由促进脂肪吸收不良的胃肠道疾病引起,导致膳食草酸吸收增加和尿草酸排泄增多。
- 肠源性高草酸尿症增加肾结石风险,严重者可致慢性肾脏病甚至肾衰竭。
- 近几十年来肠源性高草酸尿症患病率增加,主要因减重手术使用增多。
关键数值与推荐
- 当前治疗选项限于纠正潜在胃肠道疾病、强化饮食调整和使用钙盐在肠道结合草酸。
- 这些治疗对肾结石事件或慢性肾脏病等临床显著结局的证据目前缺乏。
临床怎么用
- 临床应识别脂肪吸收不良相关胃肠道疾病或减重手术史患者的高草酸尿症风险。
- 管理包括纠正胃肠道疾病、强化饮食调整和钙盐结合草酸,但需注意缺乏硬结局证据。
局限性
- 证据对现有治疗影响临床显著结局(如肾结石事件或慢性肾脏病)目前缺乏。
- 需进一步研究明确影响不良结局风险的因素、现有治疗策略的长期疗效并开发新疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Enteric hyperoxaluria is a distinct entity that can occur as a result of a diverse set of gastrointestinal disorders that promote fat malabsorption. This, in turn, leads to excess absorption of dietary oxalate and increased urinary oxalate excretion. Hyperoxaluria increases the risk of kidney stones and, in more severe cases, CKD and even kidney failure. The prevalence of enteric hyperoxaluria has increased over recent decades, largely because of the increased use of malabsorptive bariatric surgical procedures for medically complicated obesity. This systematic review of enteric hyperoxaluria was completed as part of a Kidney Health Initiative-sponsored project to describe enteric hyperoxaluria pathophysiology, causes, outcomes, and therapies. Current therapeutic options are limited to correcting the underlying gastrointestinal disorder, intensive dietary modifications, and use of calcium salts to bind oxalate in the gut. Evidence for the effect of these treatments on clinically significant outcomes, including kidney stone events or CKD, is currently lacking. Thus, further research is needed to better define the precise factors that influence risk of adverse outcomes, the long-term efficacy of available treatment strategies, and to develop new therapeutic approaches.
引用
- Witting C, Langman CB, Assimos D, et al. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2020. PMID: 32900691. doi:10.2215/CJN.08000520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。